	5		
5			
2			

2	Prevalence and clinical presentations of post-COVID-19 conditions
3	in Nepal
4	Lila Bahadur Basnet ^{1, #a} , Pomawati Thapa ^{1, #b} , Anup Bastola ¹ , Narendra Khanal ^{1, #c} , Niranjan
5	Panta ¹ , Sabin Thapaliya ² , Melissa Beth Kleine Bingham ³ , Saugat Shrestha ³ , Shital Adhikari ³ ,
6	Sudesha Khadka ^{3*} , Priyanka Shrestha ³ , Sadhana Paudel ³ , Kamaraj Arulmozhi Devapitchai ³
7	
8	¹ Department of Health Services, Curative Service Division, Ministry of Health and Population,
9	Kathmandu, Nepal
10	² Department of Internal Medicine (Infectious Diseases), Tribhuvan University Teaching Hospital,
11	Maharajgunj, Kathmandu
12	³ World Health Organization, Country office for Nepal, Pulchowk, Lalitpur
13	#aCurrent Address: College of Public Health, The University of Iowa, Iowa City, United States of
14	America
15	#b Current Address: Department of Health Services, Epidemiology and Disease Control Division,
16	Ministry of Health and Population, Kathmandu, Nepal
17	#c Current Address: Department of General Practice and Emergency Medicine, Bir Hospital,
18	Kathmandu, Nepal
19	
20	*Corresponding author
21	E-mail: khadkasudesha@gmail.com/ khadkas@who.int (SK)

22

23 Abstract

24 Introduction:

The COVID-19 pandemic affected millions worldwide. While the major focus was on diagnosis and treatment of the acute phase of the disease, many individuals experienced long-term health even after recovery. These post-COVID-19 conditions encompass a broad range of physical, psychological, and cognitive symptoms that persist beyond the acute phase of the illness. The aim of this study was to find the prevalence and reported presentations of post-COVID-19 conditions in Nepal.

31

32 Method:

This is a retrospective cross-sectional study using structured questionnaire to collect hospital-based data available in the record of Curative Service Division, Department of Health Services of Nepal from October 2021 to September 2022. A total of 6151 cases were recorded in the study. Descriptive analysis was done for demographic and symptoms variable. Association of variables to post-COVID-19 condition are shown using univariate and multivariate logistic regression.

38

39 **Results:**

Among 6151 respondents (62.25% males), more than half (59.03%) had at least one symptom after
recovery from acute COVID-19. The most common symptoms were anxiety (28.5%), loss of
appetite (25.3%), shortness of breath (24.13%), fatigue (23.24%), depressed mood (18.79%),
muscle ache (17.59%), chest pain (16.81%), headache (14.78%), and palpitation (13%).
Multivariate analysis showed increased odds of post-COVID-19 conditions in smokers (adjusted

45 OR [aOR] 1.53), those with chronic lung disease (aOR 1.71), neurological disorder (aOR 2.43) 46 and those with use of supplementary oxygen during acute illness of COVID-19 (aOR 3.37). 47 48 **Conclusion:** 49 The prevalence of post-COVID-19 symptoms among the study population is found to be high. The 50 main symptoms from our study and similar studies are anxiety, fatigue, loss of appetite, shortness 51 of breath, muscle pain, headaches. Patients with smoking, hypoxia during acute illness and 52 presence of chronic lung disease and neurological disorder had higher odds of getting post-53 COVID-19 conditions. Citing the findings, health system should focus upon the management and 54 recording of such conditions for further evidence. 55 56 57

58 Introduction

59

The COVID-19 pandemic affected millions of individuals worldwide causing significant morbidity and mortality. While the immediate focus had been on diagnosing and treating the acute phase of the disease, there is growing recognition of the long-term health consequences experienced by individuals recovering from COVID-19 [1,2]. These post-COVID-19 conditions, commonly referred to as "long COVID" or "post-acute sequelae of SARS-CoV-2 infection" (PASC), encompass a broad range of physical, psychological, and cognitive symptoms that persist beyond the acute phase of the illness [3].

67 Several studies carried out to understand the features of post-COVID conditions have shown wide 68 range of symptoms affecting the individual's ability to perform daily activities [4,5]. Though most 69 people who developed COVID-19 fully recovered, approximately 10-20% experience a variety of 70 mid- and long-term effects. The effects of the pandemic, lockdowns, guarantine, and isolation may 71 also have long-term impact. There are no tests or pathognomonic findings to establish the diagnosis 72 of post-COVID-19 conditions. Additionally, there is variability of definition and the terminology 73 used around long-COVID. The definition developed by Delphi consensus by the WHO should 74 help bring uniformity in the research and hence the data related to post-COVID-19 condition [4]. 75 Patients with post-COVID-19 condition require further healthcare services including support 76 group for post-COVID-19 condition has been widely acknowledged for their support and recovery 77 [1]. The identification of the post-COVID-19 conditions and its burden would be the basis for 78 allocation of resources and plan for needs [5]. 79 Few studies have been carried out in a single setting on post-COVID-19 conditions with limited 80 information and evidence on post-COVID-19 conditions across Nepal. This study aimed to find 81 out the prevalence and types of post-COVID symptoms in Nepalese population. 82 83 84 85 86

88 Method

89 Study Design and Setting

90 A cross-sectional study using secondary data from the electronic record and paper-based record of

91 Curative Service Division (CSD) of Department of Health Services was conducted. CSD hosted

92 the program on post-COVID and lead on the preparation of the treatment protocol for the

93 Management of Post-COVID patients. CSD is also responsible for the provision of basic health

94 services and coordination with hospitals during and beyond the COVID-19 situation.

95 Study population

96 Data (both electronic based and paper based) was recorded between October 2021 through 97 September 22 and included those who recovered from acute illness of COVID-19. The data was 98 accessed on 20th July 2023 from CSD. De-identification of accessed data was done and data with 99 incomplete information were excluded from the study.

100

101 Study tools and techniques

102 A structured questionnaire was used to collect hospital-based data available in the record of CSD.

103 The structured questionnaire was developed with reference from module 1 and module 2 of WHO

104 Case Report Form (CRF) for post-COVID condition.

105

106 Study Variable

107 Demographic details, prior comorbidities, symptoms during acute COVID-19, hospitalization and 108 oxygen use during acute COVID-19, symptoms of post-COVID-19 conditions, and history of 109 vaccination against COVID-19 were collected. Fever and cough were excluded in the analysis

because it was not clear in the record whether these symptoms reported were present in acute illness or continued after recovery. Post-COVID condition in this study is described the presence of at least one persistent or newly developed symptom one month after recovery from acute illness of COVID-19, in absence of or are not explained by other disease.

114

115 Statistical analysis

The data collected from the records were entered in Excel. Data were analyzed using Stata (version 117 17). Descriptive analysis was conducted and presented as frequencies and proportions for 118 categorical variables. Associations of post-COVID-19 symptoms with prior comorbidities and 119 various demographic data were analyzed using univariate and multivariate logistic regressions. A 120 p-value of <0.05 was considered statistically significant.

121

122 Ethical consideration

Ethical approval was obtained from National Health Research Council Ethical Review Board.
Permission to access data was obtained from the Curative Service Division. The secondary data
was used without a personal identifier.

126

127 **Results**

- 128 Of the total 6180 observations screened, 6151 observations were included in the study and the
- largest number was from the 30-39 years age group. More than half (62.25%) of the individuals
- 130 were male (Table 1). The prevalence of post-COVID-19 condition (defined here as the presence
- 131 of at least one symptom one month after recovery from acute COVID) was 59.03%.

132

Variables	Frequency	Percentage
Age group		
<=9 years	31	0.5%
10-19	140	2.3%
20-29	1417	23.0%
30-39	1662	27.0%
40-49	1094	17.8%
50-59	797	13.0%
60-69	566	9.2%
70-79	309	5.0%
80-89	126	2.0%
90 and above	9	0.1%
Sex		
Male	3829	62.3%
Female	2316	37.7%
Others	6	0.1%

133 Table 1. Socio-demographic characteristics of the screened post-COVID-19 cases

As shown in Table 2, individuals had a variety of symptoms, and many had more than one
symptom. The most common symptoms were anxiety (28.5%), loss of appetite (25.3%), shortness
of breath (24.13%), fatigue (23.24%), depressed mood (18.79%), muscle ache (17.59%), chest

- 138 pain (16.81%), headache (14.78%), and palpitation (13%). It was found that more than half
- 139 (59.03%) had at least one symptom after recovery from acute COVID-19.

140 Table 2: Characteristics of post-COVID-19 conditions (n = 6,151)

Variables	Frequency (n = 6151)	Percentage
	General Symptoms	
Fatigue	1430	23.24%
Skin rash	244	3.96%
	Cardiorespiratory symptoms	
Dyspnea	1484	24.13%
Chest pain	1034	16.81%
Palpitation	800	13.0%
	Neurology	
Headache	909	14.78%
Limb weakness	597	9.71%
Problem with gait	532	8.65%
Tremor	343	5.57%
Dizziness	306	4.97%
Numbness/tingling	225	3.65%
Fainting/Blackouts	57	0.93%
	Mental symptoms	
Anxiety	1753	28.50%
Depressed mood	1156	18.79%

Trouble concentrating	460	7.48%
Behavioral change	362	5.89%
Brain Fog	349	5.67%
Hallucination	54	0.94%

Gastrointestinal and Reproductive

Loss of appetite	1556	25.30%
Vomiting	662	10.76%
Diarrhea	603	9.80%
Constipation	510	8.29%
Abdominal pain	383	6.23%
Loss of libido	216	3.51%
	Rheumatologic	
Muscle ache	1082	17.59%
Joint pain	630	10.24%
Muscle stiffness	132	2.15%
Mei	nstrual symptoms (n = 2060)
Irregular menstruation	173	8.4% *
Dysmenorrhea	103	5.00% *
* D ()		

142 * Percentage among menstruating women

143

144 Overall, neuropsychiatric symptoms were the most prevalent followed by cardiorespiratory

symptoms. The common neuropsychiatric manifestations are shown in Fig 1.

147 Fig 1: The neuropsychiatric symptoms (shown in percentage)

148

- 149 Smokers (adjusted OR [aOR] 1.53, 95% Confidence Interval [CI] 1.34- 1.75), those with chronic
- 150 lung disease (aOR 1.71, 95% CI 1.22 2.39), neurological disorder (aOR 2.43, 95% CI 1.39-4.26),
- use of supplementary oxygen during acute illness of COVID-19 (aOR 3.37, 95% CI 2.90-3.91)
- and vaccination (any) against COVID-19 (aOR 1.72, 95% CI 1.53-1.94) had higher odds to get
- 153 post-COVID-19 condition after recovery from acute illness of COVID-19 even after adjusting for
- 154 other covariates.(Table 3)
- 155

156 Table 3: Univariate and multivariate logistic regression for outcome variables157

Variables	OR (95% CI)	p-value	aOR (95% CI)	p-value
Smoker	1.53 (1.36-1.72)	< 0.001	1.53 (1.34-1.75)	< 0.001
Male	0.71 (0.64-0.79)	< 0.001	0.66 (0.58-0.74)	< 0.001
Hypertension	1.76 (1.52-2.05)	< 0.001	1.12 (0.93-1.35)	0.24
Diabetes	1.67 (1.41-1.97)	< 0.001	1.08 (0.87-1.32)	0.49
Chronic Liver Disease	1.52 (1.01-2.31)	0.046	1.26 (0.61-2.60)	0.53
Chronic Kidney	1.01 (0.71-1.43)	0.96	0.51 (0.30-0.84)	0.009
Disease				
Chronic lung disease	2.43 (1.84-3.20)	< 0.001	1.71 (1.22-2.39)	0.002
Neurological disorder	2.21 (1.52-3.22)	< 0.001	2.43 (1.39-4.26)	0.002
Malignancy	1.44 (0.94-2.22)	0.098	0.44 (0.19-0.99)	.046
Vaccination	1.15 (1.03-1.28)	0.009	1.72 (1.53-1.94)	< 0.001

History of ICU/HDU	2.17 (1.93-2.44)	< 0.001	1.04 (0.89-1.21)	0.47
admission				
History of receiving	3.42 (3.05-3.83)	< 0.001	3.37 (2.90-3.91)	< 0.001
Oxygen therapy				

158 For regression, remaining categories in each variable were taken as reference.

159

160 **Discussion**

161 Analyzing the record of 6151 individuals with history of COVID-19 obtained, more than half were 162 found to be symptomatic. Individuals reported plethora of symptoms ranging from anxiety loss of 163 appetite shortness of breath, fatigue, persistent pain in muscles, and persistent headache. This is 164 similar to the findings from a study done in China by Huang Lixue et. al, in which the proportion 165 of patients with at least one sequelae symptom was found to be 68% (831/1227) at 6 months and 166 49% (620/1272) at 12 months. Furthermore, after one-year individuals with anxiety as a health 167 problem constituted 26 % [331/1271] and those having dyspnea were 30% [380/1271] [2]. Another 168 study done by Maxime Taquet et. al. reports 57% of the patients after whole 6 months had at least 169 one symptom [3].

The prevalence of post-COVID-19 symptoms are being measured worldwide and attempts has been made to quantify the presentations. There are variety of presentations that are difficult to collate and link to the previous COVID-19 status and hence the under-reporting is obvious. An analysis of the data from over 250,000 electronic health records also shows more than 33% presenting with the features of post-COVID-19 condition recorded between 3 and 6 months after a diagnosis of COVID-19 [6].

In a study published by B Anup et. al. from Nepal, dyspnea, fatigue, chest heaviness, and cough
were the commonest persistent complaints with 82.2% of the patients presenting with at least one
symptom [7].

Similarly, another study conducted among 300 patients in a tertiary center of Nepal shows fatigue
as the most common persistent symptom after COVID-19 illness when followed up after 3 months.
The other symptoms reported in this study are sore throat, rhinitis, diarrhea, anosmia, ageusia and
shortness of breath [8].

Different studies have shown a variety of symptoms that is linked to the previous COVID-19 illness. The duration of follow-up and the severity of illness might play a significant role in the outcomes. Globally, while there has been much effort to establish a common set of symptoms/outcomes for long-COVID, the variance and wide range of reported symptoms makes this challenging [6].

188 This study also found that smokers, patients with chronic lung disease, neurological disorder and 189 those with use of supplementary oxygen during acute illness of COVID-19 had more prevalence 190 of symptoms. In a systemic review and meta-analysis by Tsampasian V et al comprising 41 studies 191 including 860 783 patients, smoking (OR, 1.10; 95% CI, 1.07-1.13, underlying co-morbidities 192 (OR, 2.48; 95% CI, 1.97-3.13), and hospitalization and ICU admission (OR, 2.37; 95% CI, 2.18-193 2.56) were found to be the risk factors for development of post-COVID-19 conditions [9]. Multi-194 regression analysis in their study did not show diabetes and ischemic heart disease increasing the 195 risk of post-COVID-19 conditions as observed in this study.

Males had lower odds of post-COVID-19 symptoms compared to females and this could be because of the inclusion of menstrual problems and also the increased tendency to report nonspecific symptoms among females [10]. Similar findings have been reported in a multicenter study conducted in Spain [11].

People vaccinated against COVID had higher odds of post-COVID-19 symptoms than those who were not vaccinated. This contrasts with what has been reported elsewhere [9]. This could be because the symptoms following vaccination are similar to the post-COVID-19 conditions and could have been reported as post-COVID-19 symptoms [9,12]. However, this requires further investigation and was beyond the scope of this study.

Our study points to the need of tracking the patients who were hospitalized for the COVID-19 patients in hospitals of Nepal. As the COVID-19 pandemic placed the hospitals in unprecedented public health crisis, the acute illness management had been obvious primary focus. However, the growing evidence of post-COVID conditions warrants the shift in focus and consider COVID-19

as an alternative diagnosis if that is co-related.

210

211 Conclusion:

The prevalence of post-COVID-19 symptoms among the study population is found to be high. The main symptoms from our study and other similar studies include anxiety, fatigue, loss of appetite, shortness of breath, muscle pain and headache. Patients who smoked, had hypoxia during acute illness, had presence of chronic lung disease or neurological disorder had higher odds of getting post-COVID-19 conditions. Citing the findings, health system should focus upon the management and recording of such conditions for further evidence.

218

219 Acknowledgment

We would like to express our sincere gratitude to Dr. Roshan Pokharel, the Secretary of the Ministry of Health and Population, and Dr. Rajesh Sambhajirao Pandav, Country Representative for WHO, Nepal for their overall leadership and support in developing this research manuscript.

We are also deeply grateful to all individuals who are directly or indirectly involved in the entire process from conceptualization to the publication stage including those whose details are included in the study.

226 **References:**

- McNaughton CD, Austin PC, Sivaswamy A, Fang J, Abdel-Qadir H, Daneman N, et al.
 Post-acute health care burden after SARS-CoV-2 infection: a retrospective cohort study. C
- Can Med Assoc J. 2022 Oct 17;194(40):E1368–76. PubMed PMID: 36252983; PubMed
 Central PMCID: PMC9616149.
- Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021 Aug 28;398(10302):747–58. PubMed PMID: 34454673; PubMed Central PMCID: PMC8389999.
- Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study
 of 273,618 survivors of COVID-19. PLoS Med. 2021 Sep 28;18(9):e1003773. PubMed
 PMID: 34582441; PubMed Central PMCID: PMC8478214.
- World Health Organization [Internet]. Coronavirus disease (COVID-19): Post COVID-19
 condition. [cited 2023 Aug 24]. Available from: Coronavirus disease (COVID-19): Post
 COVID-19 condition (who.int)
- 242 5. Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al.
- 243 (2021) Burden of post-COVID-19 syndrome and implications for healthcare service
- 244 planning: A population-based cohort study. PLoS ONE 2021 Jul 12;16(7): e0254523.
- 245 PubMed PMID: 34252157; PubMed Central PMCID: PMC8274847.

- Munblit D, Nicholson TR, Needham DM, Seylanova N, Parr C, Chen J, et al. Studying the
 post-COVID-19 condition: research challenges, strategies, and importance of Core
 Outcome Set development. BMC Med. 2022 Feb 4;20(1):50. PubMed PMID: 35114994;
 PubMed Central PMCID: PMC8813480.
- 250 7. Bastola A, Nepal R, Shrestha B, Maharjan K, Shrestha S, Chalise BS, et al. Persistent

Symptoms in Post-COVID-19 Patients Attending Follow-Up OPD at Sukraraj Tropical and

- 252 Infectious Disease Hospital (STIDH), Kathmandu, Nepal. Trop Med Infect Dis. 2021 Jun
- 253 28;6(3):113. PubMed PMID: 34203115; PubMed Central PMCID: PMC8293320.

- Shah S, Bhattarai SR, Basnet K, Adhikari YR, Adhikari TB, Bhatta N, et al (2022) Post COVID syndrome: A prospective study in a tertiary hospital of Nepal. PLoS One. 2022 Aug
 10;17(8):e0272636. PubMed PMID: 35947595; PubMed Central PMCID: PMC9365179.
- Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. Risk
 Factors Associated With Post–COVID-19 Condition: A Systematic Review and Meta analysis. JAMA Intern Med. 2023 Jun 1;183(6):566–80. PubMed PMID: 36951832;
 PubMed Central PMCID: PMC10037203
- 10. Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in women and men. J Gen
 Intern Med. 2001 Apr;16(4):266-75. PubMed PMID: 11318929; PubMed Central PMCID:
 PMC1495200
- Fernández-De-las-peñas C, Martín-Guerrero JD, Pellicer-Valero ÓJ, Navarro-Pardo E,
 Gómez-Mayordomo V, Cuadrado ML, et al. Female Sex Is a Risk Factor Associated with
- 266 Long-Term Post-COVID Related-Symptoms but Not with COVID-19 Symptoms: The
- 267 LONG-COVID-EXP-CM Multicenter Study. J Clin Med. 2022 Jan 14;11(2):413. PubMed
- 268 PMID: 35054108; PubMed Central PMCID: PMC8778106.
- 269 12. Hosseini R, Askari N. A review of neurological side effects of COVID-19 vaccination. Eur

Z70 J Med Res. 2023 Feb 25; 28(1):102. PubMed PMID: 36841774; PubMed Central PMCID: PMC9959958

- 272 13. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of
- 273 Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis
- and Systematic Review. J Infect Dis. 2022 Nov 1;226(9):1593-1607. PubMed PMID:
- 275 35429399; PubMed Central PMCID: PMC9047189

276

277

278



